Suchergebnisse - "Visanji, Naomi P"

PubPharm (8)

1

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies

enthalten in: Frontiers in neurology | 2022

von Menon, S. | Armstrong, S. | Hamzeh, A. | +3

2

Emerging drugs for the treatment of L-DOPA-induced dyskinesia : an update

enthalten in: Expert opinion on emerging drugs | 2020

von AlShimemeri, S. | Fox, S. | Visanji, N.

3

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

enthalten in: Neuropharmacology | 2019

von Johnston, T. | Lacoste, A. | Visanji, N. | +3

4

Beyond the synucleinopathies : alpha synuclein as a driving force in neurodegenerative comorbidities

enthalten in: Translational neurodegeneration | 2019

von Visanji, N. | Lang, A. | Kovacs, G.

5

α-Synuclein-Based Animal Models of Parkinson's Disease : Challenges and Opportunities in a New Era

enthalten in: Trends in neurosciences | 2016

von Visanji, N. | Brotchie, J. | Kalia, L. | +4

6

Gastrointestinal dysfunction in Parkinson's disease

enthalten in: The Lancet. Neurology | 2015

von Fasano, A. | Visanji, N. | Liu, L. | +2

7

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

enthalten in: Movement disorders : official journal of the Movement Disorder Society | 2014

von Visanji, N. | Marras, C. | Hazrati, L. | +2

CommentIn: Mov Disord. 2014 Aug;29(9):1225-6. - PMID 24925804

8

The prion hypothesis in Parkinson's disease : Braak to the future

enthalten in: Acta neuropathologica communications | 2013

von Visanji, N. | Brooks, P. | Hazrati, L. | +1

1
[1]